Trinity Biotech Plc (TRIB): modelo de negócios [Jan-2025 Atualizado]

No mundo dinâmico do diagnóstico médico, o Trinity Biotech Plc (TRIB) surge como uma força pioneira, transformando a assistência médica por meio de soluções tecnológicas inovadoras. Ao mapear estrategicamente seu modelo de negócios em parcerias-chave, pesquisa de ponta e diagnósticos orientados a precisão, a empresa está na vanguarda de revolucionar as metodologias de testes clínicos. Sua abordagem abrangente combina perfeitamente a biotecnologia avançada, as idéias globais do mercado e um compromisso implacável em fornecer ferramentas de diagnóstico de alta precisão que capacitam os profissionais de saúde em todo o mundo.

Trinity Biotech plc (TRIB) - Modelo de negócios: Parcerias -chave

Colaboração estratégica com laboratórios de diagnóstico médico

Trinity Biotech mantém parcerias estratégicas com os seguintes laboratórios de diagnóstico:

Parceiro de laboratório	Foco de colaboração	Região geográfica
Diagnostics de missão	Testes de diagnóstico clínico	Estados Unidos
Mayo Medical Laboratories	Teste de doenças infecciosas especializadas	América do Norte
Sonic Healthcare	Desenvolvimento de Diagnóstico Molecular	Austrália/Global

Parcerias de pesquisa com instituições acadêmicas e clínicas

Trinity Biotech colabora com centros de pesquisa acadêmica:

• Faculdade de Medicina de Harvard - Pesquisa de Doenças Infecciosas
• Universidade Johns Hopkins - Diagnóstico Molecular
• University College Dublin - Inovação de Biotecnologia

Acordos de distribuição com fornecedores globais de saúde

Distribuidor	Linhas de produtos	Volume anual de distribuição
Cardinal Health	Analisadores de química clínica	US $ 12,5 milhões
Henry Schein Medical	Kits de diagnóstico de doenças infecciosas	US $ 8,3 milhões
Medline Industries	Equipamento de teste de ponto de atendimento	US $ 6,7 milhões

Alianças de fabricação com produtores especializados de equipamentos médicos

As principais parcerias de fabricação incluem:

• Thermo Fisher Scientific - Instrumentação Avançada de Diagnóstico
• Roche Diagnostics - Tecnologias de teste molecular
• Siemens Healthineers - Sistemas de Diagnóstico Clínico

Receita total de parceria: US $ 37,5 milhões em 2023

Trinity Biotech plc (TRIB) - Modelo de negócios: Atividades -chave

Desenvolvimento e fabricação de testes de diagnóstico clínico

A Trinity Biotech opera instalações de fabricação em Bray, Irlanda e Hazelwood, Missouri, EUA. Em 2022, a empresa registrou US $ 76,8 milhões em receita total da fabricação de produtos de diagnóstico.

Local de fabricação	Linhas de produto de diagnóstico	Capacidade de produção anual
Bray, Irlanda	Reagentes de Química Clínica	Mais de 500.000 kits de teste anualmente
Hazelwood, Missouri	Testes de doenças infecciosas	Aproximadamente 250.000 kits de teste anualmente

Pesquisa e inovação em diagnóstico molecular

A Trinity Biotech investiu US $ 4,2 milhões em despesas de pesquisa e desenvolvimento no ano fiscal de 2022.

• As áreas de foco incluem diagnóstico de doenças infecciosas
• Plataformas de teste moleculares para laboratórios clínicos
• Tecnologias avançadas de imunoensaio

Conformidade regulatória e garantia de qualidade

A Trinity Biotech mantém a certificação ISO 13485: 2016 para sistemas de gerenciamento da qualidade dos dispositivos médicos.

Certificação regulatória	Padrão de conformidade	Ano de certificação
Registro da FDA	21 CFR Parte 820	Mantido continuamente
Mark CE	Regulamentação européia de dispositivos médicos	Certificação atual

Teste e validação de produtos

A empresa realiza uma extensa validação clínica com mais de 50 laboratórios de referência em todo o mundo.

• Verificação abrangente de desempenho analítico
• Sensibilidade clínica e teste de especificidade
• Programas de avaliação de qualidade externa

Vendas globais e marketing de soluções de diagnóstico

A Trinity Biotech gerou US $ 76,8 milhões em receita total em 2022, com vendas internacionais representando aproximadamente 65% da receita total.

Mercado geográfico	Porcentagem de vendas	Segmentos de produtos primários
Estados Unidos	35%	Química clínica, doença infecciosa
Mercados internacionais	65%	Diagnóstico molecular, reagentes especializados

Trinity Biotech plc (TRIB) - Modelo de negócios: Recursos -chave

Instalações avançadas de pesquisa de biotecnologia

A Trinity Biotech opera instalações de pesquisa localizadas em Bray, County Wicklow, Irlanda e Carlsbad, Califórnia, EUA. Mágua quadrada total da instalação de pesquisa: 35.000 pés quadrados.

Localização	Tipo de instalação de pesquisa	Capacidade laboratorial
Bray, Irlanda	Diagnóstico molecular	20.000 pés quadrados
Carlsbad, Califórnia	Diagnóstico Clínico	15.000 pés quadrados

Força de trabalho científica e técnica especializada

Total de funcionários a partir de 2023: 213 profissionais

• Pesquisadores no nível de doutorado: 37
• Pessoal de pesquisa e desenvolvimento: 62
• Técnicos de laboratório clínico: 54
• Especialistas em garantia de qualidade: 28
• Engenheiros de fabricação: 32

Plataformas de tecnologia de diagnóstico proprietárias

Plataformas de tecnologia de diagnóstico principais:

Nome da plataforma	Tipo de tecnologia	Aplicação de mercado
MELHOR	Química Clínica	Teste de diabetes
Trinia	Diagnóstico molecular	Detecção de doenças infecciosas

Portfólio de propriedade intelectual

Total de patentes ativas: 22

• Patentes do método de diagnóstico: 12
• Patentes da plataforma de tecnologia: 7
• Patentes do processo de fabricação: 3

Capital financeiro forte

Métricas financeiras para inovação contínua:

Métrica financeira	2023 valor
Investimento em P&D	US $ 6,2 milhões
Caixa e equivalentes de dinheiro	US $ 14,3 milhões
Receita anual	US $ 87,6 milhões

Trinity Biotech plc (TRIB) - Modelo de negócios: proposições de valor

Soluções de teste de diagnóstico de alta precisão

A Trinity Biotech oferece soluções de teste de diagnóstico com as seguintes métricas de precisão:

Categoria de teste de diagnóstico	Precisão de precisão	Penetração de mercado
Testes de química clínica	99,7% de precisão	38% de participação de mercado global
Triagem de doenças infecciosas	99,5% de sensibilidade	27% de cobertura do mercado
Detecção de doenças autoimunes	99,3% de especificidade	22% de distribuição global

Gama abrangente de tecnologias de teste clínico

Breakdown do portfólio de tecnologia:

• Plataforma de imunoensaio: 6 módulos de teste diferentes
• Diagnóstico molecular: 4 sistemas de teste especializados
• Analisadores bioquímicos: 3 configurações avançadas de diagnóstico

Produtos de diagnóstico médico econômico

Métricas de eficiência de custo:

Categoria de produto	Custo médio por teste	Redução de custos em comparação aos concorrentes
Testes de diagnóstico rápido	$12.50	37% menor que a média da indústria
Kits de triagem especializados	$45.75	29% mais econômico

Métodos de detecção de doenças rápidos e precisos

Estatísticas de desempenho de detecção:

• Teste médio de tempo de resposta: 45 minutos
• Confiabilidade da detecção: 99,6% em várias categorias de doenças
• Consistência do resultado do teste: 99,8% de taxa de reprodutibilidade

Soluções inovadoras de biotecnologia para profissionais de saúde

Métricas de inovação:

Categoria de inovação	Número de tecnologias proprietárias	Investimento anual de P&D
Plataformas de diagnóstico	12 tecnologias exclusivas	US $ 18,3 milhões
Metodologias de teste patenteadas	8 patentes registradas	US $ 6,7 milhões

Trinity Biotech plc (TRIB) - Modelo de negócios: relacionamentos com o cliente

Suporte técnico direto para profissionais médicos

Trinity Biotech fornece suporte técnico por meio de:

Canal de suporte	Método de contato	Tempo de resposta
Linha técnica dedicada	Telefone: +353 1 276 9800	Dentro de 24 horas
Suporte por e -mail	support@trinitybiotech.com	Dentro de 48 horas

Programas de treinamento e educação em andamento

As ofertas de treinamento incluem:

• Série de on -line sobre tecnologias de diagnóstico
• Conferência Anual do Cliente
• Módulos de treinamento on -line

Serviços de consulta personalizados

Os serviços de consulta se concentram em:

Tipo de consulta	Público -alvo	Freqüência
Consultoria de Aplicação Clínica	Laboratórios e hospitais	Trimestral
Suporte à implementação do produto	Instituições de Saúde	Sob demanda

Plataformas de engajamento de clientes digitais

Canais de engajamento digital:

• Portal do cliente: https://portal.trinitybiotech.com
• Aplicativo móvel para rastreamento de produtos
• Canais de suporte de mídia social

Abordagem de parceria de longo prazo

Métricas de parceria:

Métrica de Parceria	2023 dados
Repetir a taxa de cliente	87.5%
Duração média do relacionamento do cliente	7,3 anos

Trinity Biotech plc (TRIB) - Modelo de negócios: canais

Equipe direta da equipe de vendas direcionada a prestadores de serviços de saúde

A Trinity Biotech emprega uma equipe de vendas direta especializada com 37 representantes de vendas a partir de 2023, com foco em:

• Hospitais
• Laboratórios Clínicos
• Centros de diagnóstico médico

Tipo de canal de vendas	Número de representantes	Cobertura geográfica
Vendas diretas de saúde	37	Estados Unidos, Europa

Plataformas de distribuição de equipamentos médicos online

Trinity Biotech utiliza plataformas digitais para distribuição de produtos, incluindo:

• Sites de comércio eletrônico de suprimentos médicos
• Mercados on -line de equipamentos de diagnóstico especializados

Apresentações da Conferência Médica e da Feira

Participação anual em conferências médicas:

Tipo de conferência	Número de eventos anuais	Alcance estimado
Conferências médicas internacionais	12	Mais de 5.000 profissionais de saúde

Informações sobre marketing digital e produtos baseados na Web

A estratégia de marketing digital inclui:

• Site da empresa com detalhes do produto
• Rede profissional do LinkedIn
• Publicidade digital direcionada

Distribuidores de equipamentos médicos especializados

A rede de distribuição inclui:

Tipo de distribuidor	Número de parceiros	Região de cobertura
Distribuidores de equipamentos médicos	24	América do Norte, Europa, Ásia

Trinity Biotech plc (TRIB) - Modelo de negócios: segmentos de clientes

Laboratórios de Diagnóstico Clínico

A Trinity Biotech atende 1.247 laboratórios de diagnóstico clínico na América do Norte e na Europa a partir de 2023.

Segmento de mercado	Número de clientes	Contribuição anual da receita
Grandes laboratórios comerciais	87	US $ 14,3 milhões
Laboratórios regionais de médio porte	342	US $ 8,7 milhões
Pequenos laboratórios locais	818	US $ 4,2 milhões

Departamentos de diagnóstico hospitalar

A Trinity Biotech fornece soluções de diagnóstico para 623 departamentos de diagnóstico hospitalar em 2023.

• Centros Médicos Acadêmicos: 87 clientes
• Hospitais comunitários: 412 clientes
• Instalações de saúde especializadas: 124 clientes

Instituições de pesquisa

O segmento de clientes de pesquisa inclui 214 clientes institucionais em 2023.

Tipo de instituição de pesquisa	Número de clientes	Uso de diagnóstico do produto
Centros de Pesquisa Universitária	129	Kits de diagnóstico especializados
Institutos de Pesquisa Privada	55	Diagnóstico molecular avançado
Instalações de pesquisa governamental	30	Plataformas de diagnóstico abrangentes

Práticas médicas privadas

A Trinity Biotech atende 1.876 práticas médicas privadas em 2023.

• Práticas de hematologia: 412 clientes
• Clínicas de oncologia: 287 clientes
• PRACTADORES GERAIS: 1.177 clientes

Sistemas de saúde pública

O segmento de clientes do Sistema de Saúde Pública inclui 356 redes de saúde afiliadas ao governo em 2023.

Região geográfica	Número de sistemas de saúde pública	Compras de diagnóstico anual de diagnóstico
Estados Unidos	187	US $ 22,6 milhões
União Europeia	124	US $ 15,3 milhões
Outros mercados internacionais	45	US $ 6,8 milhões

Trinity Biotech plc (TRIB) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Trinity Biotech registrou despesas de P&D de US $ 5,1 milhões, representando 15,3% da receita total.

Ano	Despesas de P&D ($)	Porcentagem de receita
2022	5,100,000	15.3%
2021	4,800,000	14.7%

Despesas de fabricação e produção

Os custos de fabricação da Trinity Biotech em 2022 totalizaram US $ 12,3 milhões, com um colapso da seguinte forma:

• Custos de mão -de -obra direta: US $ 4,2 milhões
• Despesas de matéria -prima: US $ 6,1 milhões
• Manutenção do equipamento: US $ 2,0 milhões

Custos operacionais de vendas e marketing

As despesas de vendas e marketing de 2022 totalizaram US $ 7,5 milhões, com a seguinte alocação:

Categoria de custo	Valor ($)
Salários do pessoal de vendas	3,600,000
Campanhas de marketing	2,100,000
Feira de feira e despesas da conferência	1,800,000

Despesas de conformidade regulatória

Os custos de conformidade regulatória da Trinity Biotech em 2022 foram de US $ 3,2 milhões, incluindo:

• Taxas de envio da FDA: US $ 1,1 milhão
• Processos de controle de qualidade: US $ 1,5 milhão
• Documentação de conformidade: US $ 600.000

Despesas globais de distribuição e logística

Os custos de distribuição e logística para 2022 totalizaram US $ 4,8 milhões, com a seguinte quebra:

Categoria de despesa	Valor ($)
Envio e transporte	2,600,000
Operações de armazém	1,400,000
Distribuição internacional	800,000

Trinity Biotech plc (TRIB) - Modelo de negócios: fluxos de receita

Vendas de equipamentos de teste de diagnóstico

Para o ano fiscal de 2023, a Trinity Biotech registrou receita de vendas de equipamentos de US $ 12,4 milhões, representando 35% da receita total da empresa.

Categoria de equipamento	Receita anual	Quota de mercado
Analisadores de química clínica	US $ 6,2 milhões	18%
Plataformas de imunoensaio	US $ 4,7 milhões	14%
Instrumentos de diagnóstico molecular	US $ 1,5 milhão	3%

Receita recorrente de kits de teste de diagnóstico

As vendas de kits de teste geraram US $ 22,6 milhões em receita recorrente para 2023, representando 52% da receita total da empresa.

• Kits de teste de doenças infecciosas: US $ 9,3 milhões
• Kits de teste de química clínica: US $ 8,1 milhões
• Kits de teste de doenças autoimunes: US $ 5,2 milhões

Licenciamento de tecnologias de diagnóstico

O licenciamento de tecnologia gerou US $ 3,1 milhões em receita para 2023, representando 7% da receita total da empresa.

Serviços de consulta e suporte técnico

Os serviços de suporte técnico e consulta contribuíram com US $ 1,9 milhão para a receita da empresa em 2023.

Receitas de expansão do mercado internacional

Região geográfica	Receita	Taxa de crescimento
Europa	US $ 8,7 milhões	6.2%
Ásia-Pacífico	US $ 5,4 milhões	9.3%
América latina	US $ 3,2 milhões	4.7%

Receita anual total: US $ 43,2 milhões

Trinity Biotech plc (TRIB) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Trinity Biotech plc (TRIB) products right now, late in 2025. It's all about delivering high-value diagnostics that cut down on cost and complexity for both patients and the healthcare system. Here's the quick math on what we're offering.

Cost-Effective, High-Volume Rapid HIV Screening (TrinScreen HIV)

The value here centers on scalability and cost control, especially after the recent manufacturing shift. Trinity Biotech plc received World Health Organization (WHO) approval in June 2025 for the offshored and outsourced upstream manufacturing of TrinScreen HIV, a move designed to unlock significant cost efficiencies and improve scalability. This positions the product favorably in the global procurement landscape, where one reference point for a similar test was listed at USD$ 0.75. The company expected a further significant quarter-on-quarter increase in revenue in Q3, 2025, as the supply of TrinScreen HIV resumed following this approval. The 2024 sales revenue forecast for this test was previously raised to over $8 million, based on total orders for 2024 reaching $6 million.

Early, Informed Decision-Making for Severe Preeclampsia Risk (PreClara™)

For maternal health, the value proposition is early, actionable insight to prevent severe outcomes. Trinity Biotech plc announced on August 14, 2025, that its New York reference laboratory received regulatory approval from the New York State Department of Health to begin offering the FDA-cleared PreClara™ Ratio biomarker test, with service rollout planned for Q3 2025. This test targets hypertensive disorders of pregnancy, which affect approximately 500,000 women annually in the United States. Incorporating the test into standard care could potentially generate neonatal cost savings exceeding $10 million per 1,000 patients, mainly by reducing preterm deliveries and NICU admissions.

Non-Invasive, 15-Day Continuous Glucose Monitoring via CGM+

The next-generation continuous glucose monitoring (CGM+) platform offers a significant technical leap over prior versions, focusing on user experience and cost reduction. Clinical trial data confirmed the redesigned, proprietary needle-free glucose sensor delivers accurate readings across a full 15-day wear period without the need for finger-stick calibration. This addresses a major hurdle in accessibility, as the company noted that the two largest CGM manufacturers serve less than 2% of the 800 million people living with diabetes worldwide, a limitation often tied to high technology costs. The technology, acquired in 2024 for $12.5 million in cash, showed a 25-30% improvement in MARD (Mean Absolute Relative Difference) over earlier models in a trial.

Here's a snapshot of the key performance metrics for the diabetes management solution:

Metric	Value/Period	Context
Wear Period	15-day	Continuous monitoring without calibration
Accuracy Improvement (MARD)	25-30% improvement	Compared to earlier Waveform CGM sensors
Global Market Size (2025 Projection)	Approximately $13 billion	Projected to reach $28 billion by 2030
Acquisition Cost (2024)	$12.5 million in cash	Cost to acquire the initial CGM assets

Comprehensive Testing and Reduced Healthcare Costs

Trinity Biotech plc is positioning its CGM+ as a multi-metric device, moving beyond simple glucose tracking. The platform supports the single device integration of several health metrics.

The value propositions related to cost reduction are supported by the company's overall financial trajectory, driven by these product improvements and operational restructuring. Trinity Biotech plc expects to be meaningfully Adjusted EBITDA-positive and cashflow positive from ongoing operating activities starting Q3 2025. This improved profitability is built on a leaner operating foundation, which includes the cost-saving manufacturing changes for TrinScreen HIV.

The core technology features that drive cost reduction include:

• Redesigned sensor reduces disposable components
• Elimination of finger-stick calibration requirement
• Reusable and rechargeable components in CGM+
• Offshoring/outsourcing manufacturing for HIV test to reduce fixed costs

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Relationships

You're looking at how Trinity Biotech plc (TRIB) manages its connections with its diverse customer base, which spans clinical labs, public health bodies, and a growing consumer segment with its new diabetes tech. The relationship strategy is definitely multi-faceted, blending direct sales efforts with platform-based digital engagement.

Dedicated direct sales force for key accounts in North America and Europe

Trinity Biotech plc sells products directly in the U.S. and U.K., relying on a sales organization that includes leadership like the Senior Vice President Global Sales and General Manager North America, a role held since 2019. The importance of these markets is clear from the 2024 revenue breakdown, showing the Americas as a primary region, though revenues there saw a slight dip in 2024. The European market, however, showed growth in 2024.

Here's a look at the latest reported regional revenue context:

Geographic Region	Revenue (Year Ended Dec 31, 2024)	Revenue (Year Ended Dec 31, 2023)
Americas	US$29,917 thousand	US$32,282 thousand
Europe	US$6,863 thousand	US$5,641 thousand

The company noted that many of its customers rely on public funding from federal, state, and local governments, which definitely impacts the stability of these commercial relationships.

High-touch support for clinical lab instrument installation and training

For its clinical laboratory segment, the relationship is built on the delivery and maintenance of instrumentation. While specific 2025 support metrics aren't public, the company operates a New York reference laboratory offering testing services for autoimmune disorders, indicating a direct, high-touch service component for that segment.

Long-term contracts with public health authorities for HIV testing

Relationships with public health authorities are crucial, especially for the Uni-Gold HIV rapid test, a cornerstone product in international HIV screening programs. Demand from these bodies can be lumpy; for instance, sales of TrinScreen HIV reached $3.2 million in Q4 2024, contributing to a revised 2024 sales forecast of approximately $10 million for that specific test. Uncertainty around U.S. government HIV test funding caused production pullbacks in Q1 2025.

A major recent development in this relationship area is the November 2025 World Health Organization (WHO) approval for the offshored and outsourced upstream manufacturing of the Uni-Gold HIV test. This transition, which took approximately two years to develop, is expected to improve gross margin, EBITDA, and cashflow generation, streamlining operations for these key public health customers.

Digital engagement and real-time analytics for the CGM+ consumer base

The relationship model shifts significantly with the next-generation Continuous Glucose Monitoring (CGM) solution, CGM+. This platform is designed for the $260 billion AI wearables market, targeting both diabetes patients and health-conscious consumers. The engagement model is centered on recurring revenue potential through AI analytics subscriptions.

Key performance indicators from the redesigned sensor in pre-pivotal testing highlight the value proposition driving this engagement:

• No finger-stick calibration required over a full 15-day sensor wear period.
• Approximately 35% better Mean Absolute Relative Difference (MARD) compared to the prior Waveform product.
• More than 50% improvement in Mean Absolute Difference (MAD) over the prior Waveform product.

The trial involved 30 participants, primarily with Type 1 diabetes. Trinity Biotech plc anticipates commercial launch of CGM+ in mid-2026, with a U.S. FDA filing planned for 2026.

Regulatory compliance and quality assurance to maintain trust (defintely crucial)

Maintaining trust is non-negotiable, especially when dealing with diagnostic products and medical devices. The recent WHO approval for the Uni-Gold HIV test manufacturing change explicitly states the company will retain the highest levels of product integrity and regulatory compliance during the transition. This focus on compliance is the bedrock for all customer relationships, from public health bodies to individual CGM users.

The company's Q1 2025 revenue estimate of US$7.0 million to US$8.0 million was substantially below Q1 2024, partly due to deferred manufacturing while changing locations, underscoring how operational changes tied to quality and location impact commercial flow.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Channels

You're looking at how Trinity Biotech plc gets its diagnostic products and services into the hands of healthcare providers as of late 2025. The channel strategy clearly splits based on geography and product type, which is typical for a company with a diverse portfolio spanning central labs and point-of-care.

Direct sales teams targeting hospitals and reference laboratories form the backbone of their presence in key, high-value markets. Trinity Biotech plc serves a worldwide customer base through direct sales operations specifically in North America and Europe. This direct approach is used for certain high-value instruments, such as the Premier Hb9210 HbA1c analyzer, in the USA and Brazil. The clinical laboratory segment, which relies on these direct channels for service and support, generated revenues of $44.1m for the full year ended December 31, 2024. The company's Q1 2025 revenue guidance was between US$7.0 million to US$8.0 million, reflecting a transitional period where manufacturing ramp-up impacts immediate channel fulfillment.

The network of independent distributors across Asia Pacific and the Middle East, along with Latin America, handles much of the international reach for Trinity Biotech plc. This distributor model is employed for the Premier Hb9210 in the rest of the world outside the direct sales territories. The company's success is highly dependent on servicing and supporting products through these strategic partners. For instance, in the Middle East, distributors like GULF PHARMACY AND GENERAL STORE in Bahrain and Ronoc TEB in Iran are listed as channel partners. In Asia Pacific, Progressive International Holding Co Ltd in China and Biozen in Thailand represent this distribution layer.

Here's a look at the revenue segmentation from the most recently reported full fiscal year, which gives you a sense of the scale each major channel grouping supports:

Channel/Segment Focus	FY 2024 Revenue (USD)	FY 2024 Revenue Percentage (of $61.6m TTM)
Clinical Laboratory (Mix of Direct/Distributor)	$44.1m	Approx. 71.6%
Point-of-Care (PoC) (Mix of Direct/Distributor)	$17.5m (Calculated: $61.6m - $44.1m)	Approx. 28.4%

Reference laboratory services for specialized testing (e.g., PreClara™) are a key part of the Clinical Laboratory channel. Trinity Biotech plc received regulatory approval to begin its FDA-cleared PreClara™ Preeclampsia Testing Service, positioning this specialized offering within the reference lab channel. The overall Clinical Laboratory revenues for FY 2024 were $44.1m, a decrease of 7.6% year-on-year from $47.7m in FY 2023. The company also provides raw materials to the life sciences industry globally, which is another service-based revenue stream.

The online and app-based platform for the CGM+ wearable biosensor represents a future-facing channel, though concrete 2025 sales data is not yet public. Trinity Biotech plc is actively analyzing results from pre-pivotal testing on its updated CGM sensor, which promises a 15-day usage period without recalibration. This technology is designed to transform glucose monitoring into a seamless, fingertip-free experience, suggesting a future direct-to-consumer or direct-to-clinic digital sales/subscription component, though the current focus remains on development and regulatory milestones.

Global tenders and procurement processes for public health products are critical for high-volume sales of rapid tests, such as the TrinScreen HIV test. The company secured regulatory approval for its offshored and outsourced manufacturing of its flagship rapid HIV test, which is expected to underpin a significant quarter-on-quarter revenue increase in Q3, 2025, following WHO approval. Sales of TrinScreen HIV were $10.0m for the full year 2024, up from $0.4m in 2023, showing the impact of large-scale procurement channels.

• Direct Sales Focus: North America and Europe.
• Distributor Focus: Asia Pacific, Latin America, and the Middle East.
• Direct Sales for Premier Hb9210: USA and Brazil.
• FY 2024 Clinical Lab Revenue: $44.1m.
• FY 2024 TrinScreen HIV Sales: $10.0m.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Customer Segments

You're looking at the core groups Trinity Biotech plc (TRIB) serves with its diagnostic and diabetes management portfolio. Honestly, it's a diverse set of buyers, ranging from large centralized labs to individual patients managing chronic conditions. The company markets its several hundred products to customers in approximately 100 countries globally. A majority of the revenue is derived from the Americas segment.

Here's a breakdown of the distinct customer segments Trinity Biotech plc targets:

• Clinical and reference laboratories globally
• Public health authorities and NGOs (e.g., for HIV screening)
• Hospitals and clinics focused on maternal health (preeclampsia testing)
• Diabetics and healthcare providers for continuous glucose monitoring
• Life sciences and research industries (raw materials supply)

The scale of the business, based on late 2024 financials, shows a trailing twelve-month revenue of $61.6M. The company expected Q1 2025 revenue to be between US$7.0 million to US$8.0 million, with a ramp-up expected by late Q2 to Q3 2025.

The primary customer groups and relevant data points are detailed below:

Customer Segment	Key Trinity Biotech Offering	Relevant Market/Customer Data
Clinical and Reference Laboratories	In vitro diagnostic systems, reagents, instrumentation, Immco lab services	Diagnostic laboratories accounted for the highest market share of 45.9% in the global HIV diagnostics market in 2024. Trinity Biotech sells directly in the United States, Brazil, Germany, France, and the U.K..
Hospitals and Clinics (Maternal Health Focus)	FDA-cleared PreClara Ratio (sFlt-1/PlGF) biomarker test service	The service targets hypertensive disorders of pregnancy, which impact approximately 500,000 women in the United States every year. Incorporation of the test could yield neonatal cost savings exceeding $10 million per 1,000 patients.
Public Health Authorities and NGOs	Uni-Gold™ HIV rapid test, TrinScreen HIV	The global HIV diagnostics market was projected at $2.6 billion in 2025. Trinity Biotech's Uni-Gold test received WHO approval in November 2025 for its outsourced manufacturing. TrinScreen HIV sales were $3.2M in Q4 2024.
Diabetics and Healthcare Providers	Wearable biosensors, Continuous Glucose Monitoring (CGM) product development, Hemoglobin A1c analyzers	Trinity Biotech entered the biosensor industry with the acquisition of Waveform Technologies Inc.'s assets to develop a CGM product. Products quantify the level of Haemoglobin A1c.
Life Sciences and Research Industries	Raw materials supply	Trinity Biotech plc provides raw materials to the life sciences and research industries globally.

For infectious disease testing, Trinity Biotech plc offers serological and rapid tests for diseases like HIV and hepatitis B and C, used by these facilities to support diagnosis and treatment monitoring. The Point-of-Care (PoC) portfolio generated revenue of $5.5M for Q4 2024.

The company's strategy involves direct sales in key markets like the US, and a distributor network covering the rest of the world. You should note that the clinical laboratory revenue segment saw a decrease of $3.6M year-over-year for the full year 2024, down to $44.1M.

The focus on maternal health with the PreClara Ratio test, launched in Q3 2025, is a strategic move to enhance the position in a critical clinical area. Also, the company is working on PrePsia™, its proprietary preeclampsia risk assessment technology for early pregnancy, with first revenues expected in 2025 following the September 2024 acquisition of Metabolomics Diagnostics.

For the HIV segment, the company is streamlining operations, with the outsourcing of Uni-Gold™ manufacturing expected to improve gross margins and EBITDA. Finance: review the Q1 2025 actuals against the $7.0M - $8.0M projection by end of next week.

Trinity Biotech plc (TRIB) - Canvas Business Model: Cost Structure

You're looking at the expenses Trinity Biotech plc is managing as it pushes through its transformation plan. Honestly, the cost structure is dominated by the core business of manufacturing diagnostics and the heavy investment needed for the new Continuous Glucose Monitoring (CGM) platform.

The most significant component is the Cost of Goods Sold (COGS), which reflects the direct costs of producing their diagnostic kits and reagents. For the full twelve months ended December 31, 2024, the Cost of Sales was reported at $40,114 thousand, up from $37,382 thousand in 2023. This shows the pressure from raw materials and manufacturing scale, even as they work on efficiencies.

To drive future savings, Trinity Biotech plc took a hit in 2024. They incurred restructuring and other one-off costs totaling $6.1 million for the year ended December 31, 2024. This was part of the Comprehensive Transformation Plan to consolidate and offshore manufacturing and corporate services. The company expects this aggressive restructuring to lead to a leaner cost base, projecting they will be meaningfully Adjusted EBITDA positive and cash flow positive from ongoing operating activities starting in the third quarter of 2025. For context on the quarterly impact, Q4 2024 included restructuring, impairment, and one-off costs totaling $4.7 million.

Research and development (R&D) remains a key cost area, particularly for the new CGM technology. For the full year 2024, Research and development expenses were US$4.5 million, a slight increase from US$4.4 million in 2023. You see this investment flow into assets, too; for instance, the largest element of investing cash outflows in Q4 2024, at $2.7 million, pertained to the capitalization of development costs for their CGM device.

The Selling, General, and Administrative (SG&A) expenses reflect the cost of supporting the global sales teams across over 75 countries. For the full year 2024, SG&A was $28.8 million, which was a favorable decrease of $2.3 million compared to 2023, driven by organizational realignment measures.

Financing costs are tied to the debt load. While you mentioned approximately $100.8 million, the balance sheet as of December 2024 showed total debt of $0.10 Billion USD. The Net financing expense for the full year 2024 was $9.6 million, down from $9.9 million in 2023.

Here's a quick look at the major expense lines for the full year 2024 compared to 2023 (all figures in US$000s unless noted):

Cost Category	Twelve Months Ended Dec 31, 2024 (US$000's)	Twelve Months Ended Dec 31, 2023 (US$000's)
Cost of Sales	(40,114)	(37,382)
Research & development expenses	4,500	4,400
Selling, general and administrative expenses	28,800	31,100
Restructuring and other once off costs	6,100	0
Net financing expense	9,600	9,900

The operational focus is clearly on cost reduction, as evidenced by the SG&A decrease and the restructuring charges. You can see the impact of the transformation plan in the quarterly figures, too:

• SG&A expenses in Q3 2024 were $6.5 million, down from $7.7 million in Q3 2023.
• SG&A expenses in Q2 2024 were $6.4 million, down from $7.9 million in Q2 2023.
• The company is exiting sub-scale, lower-margin third-party product lines that previously generated approximately $3 million in annual revenue in 2024.
• The Senior secured term loan component of non-current liabilities was $72,391 thousand as of December 31, 2024.

If onboarding for the new manufacturing structure takes longer than expected, churn risk rises.

Finance: draft 13-week cash view by Friday.

Trinity Biotech plc (TRIB) - Canvas Business Model: Revenue Streams

You're looking at the core ways Trinity Biotech plc brings in money right now, as of late 2025. It's a mix of established diagnostics and newer, high-potential areas, especially as they exit their restructuring phase.

The primary, immediate revenue sources are tied to the sales of clinical laboratory products and instrumentation, alongside their Point-of-Care (PoC) offerings. For the trailing twelve months ending in December 2025, Trinity Biotech plc's total revenue stands at approximately $61.55 Million USD. This figure reflects the ramp-up following operational changes.

Looking at recent quarterly performance gives you a clearer picture of the momentum. For instance, Q1 2025 revenue was reported at $7.6 million. Management projected a significant sequential jump for Q2 2025, guiding revenue to a range of $11 million to $12 million. This growth was expected to be driven by normalized demand for their rapid HIV tests and stabilized manufacturing.

The Point-of-Care (PoC) segment is a key driver, notably through the TrinScreen HIV test. While the full-year 2024 guidance for TrinScreen HIV sales was set around $10 million, Q4 2024 saw sales of $3.2 million for that specific test alone. The company had previously targeted an annualized run rate revenue of around $75 million by Q2 2025 based on Q3 2024 projections.

Here's a breakdown of the revenue components based on the most recent segment data available:

Revenue Stream Category	Specific Metric/Period	Amount
Trailing 12-Month Revenue (TTM)	As of December 2025	$61.55 Million USD
Projected Quarterly Revenue	Q2 2025 Range	$11 million to $12 million
Reported Quarterly Revenue	Q1 2025	$7.6 million
Point-of-Care (PoC) Revenue	Q4 2024	$5.5 million
Clinical Laboratory Revenue	Q4 2024	$10.3 million
TrinScreen HIV Sales	Q4 2024	$3.2 million

Beyond the immediate diagnostics, Trinity Biotech plc is positioning for future recurring revenue, particularly in diabetes management. The next-generation Continuous Glucose Monitoring (CGM+) platform, though anticipated for commercial launch in mid-2026, is designed to open multiple revenue streams.

Future revenue potential is clearly mapped out:

• Device sales from the CGM+ platform.
• AI analytics subscriptions and related services tied to the CGM+ system.
• Revenue from the preeclampsia test, which was expected to start generating revenue in the second half of 2025.
• Strategic partnerships with healthcare providers and insurers related to the new biosensor technology.

The successful WHO approval for offshored manufacturing of TrinScreen HIV is also set to underpin further revenue increases starting in Q3 2025.